KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $452.0 million.

  • Royalty Pharma's Net Cash Flow rose 137.69% to $307.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year decrease of 181.65%. This contributed to the annual value of $452.0 million for FY2024, which is 136.64% up from last year.
  • Latest data reveals that Royalty Pharma reported Net Cash Flow of $452.0 million as of FY2024, which was up 136.64% from -$1.2 billion recorded in FY2023.
  • Over the past 5 years, Royalty Pharma's Net Cash Flow peaked at $762.5 million during FY2020, and registered a low of -$1.2 billion during FY2023.
  • In the last 3 years, Royalty Pharma's Net Cash Flow had a median value of $169.7 million in 2022 and averaged -$204.0 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first spiked by 145.44% in 2020, then plummeted by 827.00% in 2023.
  • Yearly analysis of 5 years shows Royalty Pharma's Net Cash Flow stood at $762.5 million in 2020, then plummeted by 30.18% to $532.4 million in 2021, then plummeted by 68.12% to $169.7 million in 2022, then plummeted by 827.00% to -$1.2 billion in 2023, then skyrocketed by 136.64% to $452.0 million in 2024.